Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of “Hold” from Brokerages

Sight Sciences, Inc. (NASDAQ:SGHT) has been given a consensus rating of “Hold” by the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $8.7625.

A number of equities analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Citigroup lifted their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. William Blair reissued an “outperform” rating on shares of Sight Sciences in a research report on Thursday. Raymond James Financial set a $9.00 price objective on Sight Sciences in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th.

Key Stories Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; loss narrowed. Sight Sciences reported Q4 EPS of ($0.08) vs. consensus ($0.15) and revenue of $20.39M, showing a return to quarterly revenue growth and a smaller loss vs. last year. Article Title
• Positive Sentiment: Operational improvement: margins and expense cuts. Gross margins remained high (Q4 ~87%), and the company cut operating expenses substantially year-over-year, reducing quarterly cash use and lowering net loss. Article Title
• Positive Sentiment: Management projects revenue growth and dry eye ramp in 2026. Guidance calls for $82M–$88M revenue (6%–14% growth) with Interventional Dry Eye expected to grow to $5M–$7M, indicating management expects a material commercial ramp. Article Title
• Neutral Sentiment: Balance sheet: meaningful cash but outstanding debt. Cash was $92M at year-end with $40M of long-term debt — healthy but reduced cash vs. 2024. This gives runway but investors will watch burn and breakeven timing. Article Title
• Neutral Sentiment: Analyst commentary is mixed but includes optimism. Some brokers (e.g., Stifel) see upside after the print, but the guidance mix creates debate among analysts. Article Title
• Negative Sentiment: Guidance sits slightly below consensus and raises expense outlook. The $82M–$88M revenue range compares to a consensus ~$86.5M and adjusted operating expenses are expected to rise to $93M–$96M as the company invests to scale — a near-term earnings headwind. Article Title
• Negative Sentiment: Full-year 2025 revenue declined and dry eye remains a weak spot. Full-year revenue fell ~3% to $77.4M and Interventional Dry Eye revenue dropped to $1.6M in 2025 (from $4.0M), raising execution risk on the planned ramp. Article Title
• Negative Sentiment: Insider selling and elevated volatility. Recent insider sales and heavy trading volume on the print increase downside risk and contributed to the share-price decline. Article Title

Insider Buying and Selling

In other news, CFO James Rodberg sold 4,405 shares of Sight Sciences stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $34,447.10. Following the transaction, the chief financial officer directly owned 154,440 shares of the company’s stock, valued at $1,207,720.80. The trade was a 2.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO David Badawi sold 4,836 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $6.62, for a total value of $32,014.32. Following the transaction, the chief technology officer owned 1,912,273 shares of the company’s stock, valued at approximately $12,659,247.26. This trade represents a 0.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 99,796 shares of company stock worth $719,722 over the last ninety days. 30.90% of the stock is owned by corporate insiders.

Institutional Trading of Sight Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new stake in shares of Sight Sciences during the 1st quarter valued at $128,000. Strs Ohio bought a new stake in Sight Sciences during the first quarter valued at about $158,000. Rhumbline Advisers lifted its position in shares of Sight Sciences by 9.5% in the first quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock valued at $120,000 after acquiring an additional 4,319 shares in the last quarter. CWM LLC boosted its stake in shares of Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after acquiring an additional 3,137 shares during the period. Finally, Bank of Montreal Can bought a new position in shares of Sight Sciences in the second quarter worth about $49,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Stock Performance

Shares of SGHT opened at $3.96 on Friday. The firm has a market capitalization of $209.37 million, a P/E ratio of -5.28 and a beta of 2.43. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93. Sight Sciences has a one year low of $2.03 and a one year high of $9.24. The business has a fifty day moving average of $6.29 and a 200 day moving average of $5.75.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.07. The company had revenue of $20.39 million for the quarter, compared to the consensus estimate of $20.35 million. Sight Sciences had a negative return on equity of 54.39% and a negative net margin of 49.67%. As a group, sell-side analysts anticipate that Sight Sciences will post -0.99 EPS for the current year.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.